DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypermobility syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypermobility syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypermobility syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
5-hydroxytryptamine receptor 3A (HTR3A) — HTR3A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet vtxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8BLB · 3.3 Å · ligand Vortioxetine (VTX). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine Clinical Cases · 2022 · 0 citations · open access
Hospital Stay Considerations in Hypermobile Ehlers-Danlos Syndrome: An Exemplary Case With Insights for Coexisting Symptoms
AbstractEhlers-Danlos syndrome, hypermobility type, is a complex medical condition understood to be a genetic disorder resulting in abnormal collagen synthesis. It is characterized by joint hypermobility as well as skin laxity, poor wound healing, and other manifestations. It may present in conjunction with autonomic, neurologic, and immune abnormalities. Hypermobility spectrum disorder is similarly characterized by joint hypermobility but holds less extensive diagnostic criteria. When in the hospital setting, systemic differences resulting from hypermobility syndromes must be recognized to avoid harm. Here, we present the first case, to our knowledge, of a full hospital course with hypermobility syndrome–comorbidity-related complications described.
Annals of Advanced Biomedical Sciences · 2023 · 0 citations · open access
Joint Hypermobility Syndrome: 2 Cases from the Capital of the Cherokee Nation and Review of Literature
AbstractJoint Hypermobility Syndrome (JHS) includes a spectrum of disorders that can be difficult to differentiate. Often overlapping or nonspecific symptoms can confound the diagnosis. The prevalence of JHS is much higher than the hypermobility variant of EDS (hEDS), although the latter is being diagnosed more especially with Brighton criteria that incorporate the Beighton score [1]. While other connective tissue disorders resulting in joint hypermobility may have specific genetic markers, the hEDS so far does not. This often requires clinicians to have a high index of suspicion for hEDS, or it may go undiagnosed, therefore leaving particularly young patients with a chronic debilitating disease without answers for their symptoms. Here we present two cases of JHS from the capital of the Cherokee Nation diagnosed relatively late compared to the average age at diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
